Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Medtronic enters the week with its most striking short-side development in months: borrowed shares have more than doubled in seven days, yet the lending market remains wide open and borrow costs are near their lowest levels of the quarter.
The short interest build is the number that demands attention. Estimated short positions climbed 115% over the past week to 37.5 million shares, equivalent to about 2.9% of free float. That is still a low absolute level, but the pace is unusual. From mid-August through late September, short interest barely moved, holding in a narrow band around 14 million shares. Then it broke higher through October, jumping from 17.4 million on September 30 to 37.5 million on October 6, a near doubling in four trading sessions. The ORTEX short score has tracked this, rising from 29.8 on September 30 to 37.5 on October 6, its highest reading in the 30-day window. For a stock that had been sitting quietly in the low 30s, that acceleration is worth watching. Yet the borrow market tells a very different story. Availability remains enormous, roughly 907 shares available for every 100 already borrowed, a ratio that makes any short-squeeze narrative hard to sustain. Cost to borrow is back down to 0.57%, near the low end of its recent range after a brief spike above 8% on September 23. Shorts are building positions cheaply and easily. Options positioning adds mild confirmation of the cautious tone. The put/call ratio is 0.62, modestly above its 20-day average of 0.60, but barely a third of a standard deviation from the mean and well short of the 52-week high of 0.74. Options markets are not amplifying the short-side message.
The Street remains firmly anchored in the other direction, and the gap between analyst conviction and market price has not closed. The mean analyst price target is $104.44, implying more than 19% upside from the current $87.09 close. That disconnect, flagged in the previous note published on September 30, has widened slightly since. Barclays initiated coverage this morning with an Equal-Weight rating and a $95 target, the only fresh action on the stock this week. The initiation slots in below the bull camp but above the current price, adding a neutral-leaning voice to a consensus that otherwise leans constructive. Bulls point to FY1Q27 results that beat estimates on revenue of $9.756 billion and adjusted EPS of $1.45, 13.7% organic growth, Cardiac Ablation Solutions surpassing $2 billion in trailing revenue ahead of schedule, and management raising full-year guidance. Bears focus on the risk that newer platforms in robotics, renal denervation, and pulsed-field ablation fail to offset mature product pressure, and that tariff and input-cost headwinds compress margins further than guidance implies. Valuation sits at a trailing PE of 13.8 and EV/EBITDA of 11.6, both drifting lower over the past 30 days as the stock has fallen 7.5% over the month. The dividend score ranks in the 90th percentile of the ORTEX universe, giving income-oriented holders a reason to stay patient while the growth story plays out.
One alternative data point is worth noting this week. Wikipedia views for Medtronic are running at a z-score of 2.4 relative to the prior 90-day average, meaning retail attention is meaningfully elevated against recent norms. This is an attention signal, not a revenue indicator, and none of Medtronic's alt-data datasets have been measured to lead its reported figures. The next earnings print is scheduled for November 24, 48 days away.
The sector context provides little relief. Closest peers had a rough week too. BSX fell 3.9% on the week, ABT dropped 2.8%, and ZBH slid 1.8%. Medtronic was flat on the week overall but has lost 7.5% over the past month, and the peer group weakness suggests this is a sector-level re-rating rather than stock-specific selling pressure. Institutional ownership remains heavily concentrated in passive and large active managers, with BlackRock holding 8.9% and Vanguard entities collectively holding more than 10%, groups unlikely to be driving the short-side activity.
The picture coming into November 24 is one of a stock drifting lower against a backdrop of rising, but still modest, short positioning, an unshaken Street consensus, and a borrow market that makes further short-side accumulation frictionless. Whether the short build accelerates toward earnings or fades as quickly as it appeared is the key dynamic to track in the coming weeks.
See the live data behind this article on ORTEX.
Open MDT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
